349TiP EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) + nab-paclitaxel (nab-PTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation

Triple Negative ◽

Pik3ca Mutation ◽

Phase Iii ◽

Controlled Study ◽

Double Blind ◽

Phosphatase And Tensin Homolog ◽

Pten Loss ◽

Tensin Homolog

248TiP A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.369 ◽

2020 ◽

Vol 31 ◽

pp. S339

Author(s):

S. Loibl ◽

P. Rastogi ◽

S. Seiler ◽

C. Jackisch ◽

P.C. Lucas ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial

IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)

Annals of Oncology ◽

10.1093/annonc/mdy424.008 ◽

2018 ◽

Vol 29 ◽

pp. viii707-viii708 ◽

Cited By ~ 3

Author(s):

P. Schmid ◽

S. Adams ◽

H.S. Rugo ◽

A. Schneeweiss ◽

C.H. Barrios ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Phase Iii ◽

Double Blind ◽

Treatment Naïve ◽

Phase Iii Study

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Annals of Oncology ◽

10.1093/annonc/mdx656 ◽

2017 ◽

Vol 28 ◽

pp. x25

Author(s):

J. Cortes Castan ◽

Z. Guo ◽

V. Karantza ◽

G. Aktan

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Study ◽

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

10.1158/1538-7445.am2017-ct069 ◽

2017 ◽

Cited By ~ 1

Author(s):

Javier Cortes ◽

Zifang Guo ◽

Vassiliki Karantza ◽

Gursel Aktan

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Study ◽

Faculty Opinions recommendation of KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.733209651.793559074 ◽

2019 ◽

Author(s):

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Study ◽

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Annals of Oncology ◽

10.1093/annonc/mdx364.016 ◽

2017 ◽

Vol 28 ◽

pp. v72

Author(s):

J. Cortes Castan ◽

Z. Guo ◽

V. Karantza ◽

G. Aktan

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Study ◽

Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab +nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer

10.1158/1538-7445.sabcs18-gs1-04 ◽

2019 ◽

Cited By ~ 24

Author(s):

LA Emens ◽

S Loi ◽

HS Rugo ◽

A Schneeweiss ◽

V Diéras ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Treatment Naïve ◽

Phase Iii Study

Abstract OT1-08-03: Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence

10.1158/1538-7445.sabcs19-ot1-08-03 ◽

2020 ◽

Cited By ~ 1

Author(s):

Hope S Rugo ◽

Louis WC Chow ◽

Javier Cortes ◽

Peter A Fasching ◽

Binghe Xu ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Triple Negative ◽

Early Stage ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo

Annals of Oncology ◽

10.1093/annonc/mdz097.014 ◽

2019 ◽

Vol 30 ◽

pp. iii38

Author(s):

S. Loibl ◽

C. Jackisch ◽

P. Rastogi ◽

S. Seiler ◽

P.C. Lucas ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Neoadjuvant Chemotherapy ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Clinical Trial

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Annals of Oncology ◽

10.1016/j.annonc.2021.05.801 ◽

2021 ◽

Author(s):

D. Miles ◽

J. Gligorov ◽

F. André ◽

D. Cameron ◽

A. Schneeweiss ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo